Control Bionics Limited (ASX:CBL)

Market Cap	11.49M
Revenue (ttm)	5.28M
Net Income (ttm)	-6.95M
Shares Out	294.61M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	660,429
Average Volume	173,942
Open	0.0390
Previous Close	0.0390
Day's Range	0.0350 - 0.0390
52-Week Range	0.0340 - 0.1050
Beta	0.07
RSI	46.43
Earnings Date	May 26, 2025

About Control Bionics

Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. The company offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. It also provides Cosmos Connect, a small portable control device that ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2005
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CBL

Financial Performance

In 2024, Control Bionics's revenue was 5.35 million, a decrease of -5.17% compared to the previous year's 5.64 million. Losses were -5.91 million, 5.02% more than in 2023.